BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 02 2020 - 7:15AM
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced
that the compensation committee of BioCryst’s board of directors
granted five newly-hired employees inducement options to purchase
an aggregate of 147,500 shares of BioCryst common stock on May 29,
2020 as inducements material to each employee entering into
employment with BioCryst. The options were granted in accordance
with NASDAQ Listing Rule 5635(c)(4).
The options have an exercise price of $4.50
per share, which is equal to the closing price of BioCryst common
stock on the last business day prior to the grant date. The
options vest in four equal annual installments beginning on the
one-year anniversary of the grant date, in each case subject to the
new employee’s continued service with the company. Each stock
option has a 10-year term and is subject to the terms and
conditions of BioCryst’s Inducement Equity Incentive Plan and a
stock option agreement covering the grant.
About BioCryst
Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral,
small-molecule medicines that treat rare diseases in which
significant unmet medical needs exist and an enzyme plays a key
role in the biological pathway of the disease. BioCryst has several
ongoing development programs including berotralstat (BCX7353), an
oral treatment for hereditary angioedema, BCX9930, an oral Factor D
inhibitor for the treatment of complement-mediated diseases,
galidesivir, a potential treatment for COVID-19, Marburg virus
disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the
treatment of fibrodysplasia ossificans progressiva. RAPIVAB®
(peramivir injection), a viral neuraminidase inhibitor for the
treatment of influenza, is BioCryst's first approved product and
has received regulatory approval in the U.S., Canada, Australia,
Japan, Taiwan, Korea and the European Union. Post-marketing
commitments for RAPIVAB are ongoing. For more information, please
visit the Company's website at www.BioCryst.com.
BCRXW
Contact:John Bluth+1 919 859
7910jbluth@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Sep 2023 to Sep 2024